EGFR:
- Percent Cases Positive: 23%
- Methods: DNA Sequencing, Polymerase Chain Reaction
- Associated Therapies: gefitinib (Iressa), erlotinib (Tarceva), afatinib (Gilotrif), Osimertinib (Tagrisso), Dacomitinib (Vizimpro), necitumumab (Portrazza)
- Percent Cases Positive: 6%
- Methods: Fluorescence in situ hybridization, Immunohistochemistry, Next-Generation Sequencing
- Associated Therapies: Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena)
- Percent Cases Positive: 3%
- Methods: DNA Sequencing, Polymerase Chain Reaction
- Associated Therapies: Dabrafenib (Tafinlar), Trametinib (Mekinist)
- Percent Cases Positive: 25%
- Methods: Sanger Sequencing, Polymerase Chain Reaction, Next-Generation Sequencing
- Associated Therapies: None, KRAS-mutation positive is indicative of resistance to EGFR therapies
- Percent Cases Positive: 1%
- Methods: Immunohistochemistry, Fluorescence in situ hybridization
- Associated Therapies: Trastuzumab (Herceptin), Afatinib (Gilotrif)
- Percent Cases Positive: 1.5%
- Methods: Immunohistochemistry, Fluorescence in situ hybridization, Next-Generation Sequencing, Real-Time Polymerase Chain Reaction
- Associated Therapies: Crizotinib (Xalkori), Ceritinib (Zykadia)
- Percent Cases Positive: 30%
- Methods: Immunohistochemistry
- Associated Therapies: nivolumab (Opdivo), pembrolizumab (Keytruda), atezolizumab (Tecentriq), durvalumab (Imfinzi), avelumab (Bavencio)